Immune-Onc Therapeutics Revenue
Biotechnology Research • 
Palo Alto, California, United States • 11-20 Employees
Immune-Onc Therapeutics revenue & valuation
| Annual revenue | $5,000,000 |
| Revenue per employee | $295,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $16,000,000 |
| Total funding | $25,000,000 |
Key Contacts at Immune-Onc Therapeutics
Xiao Min Schebye
Senior Director
Tao Huang
Senior Director
Austin Gurney
Member, Board Of Directors
Stella Yan
Director Of Hr And Operations China
Company overview
| Headquarters | 795 San Antonio Rd, Palo Alto, California 94303, US |
| Phone number | +16504607691 |
| Websites | |
| NAICS | 541714 |
| SIC | 873 |
| Founded | 2016 |
| Employees | 11-20 |
| Socials |
Immune-Onc Therapeutics Email Formats
Immune-Onc Therapeutics uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@immuneonc.com), used 57.1% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@immuneonc.com | 57.1% |
{first name}.{last name} | john.doe@immuneonc.com | 42.9% |
About Immune-Onc Therapeutics
Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a private, clinical-stage oncology company dedicated to discovering and developing novel biotherapeutics targeting myeloid cell inhibitory receptors. Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies. Immune-Onc has a differentiated pipeline with a current focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB). Immune-Onc’s focused platform approach has led to the development of several promising therapeutics across various stages of development. Those include IO-108, an antagonist antibody targeting LILRB2 (also known as ILT4), in Phase 1b/2 clinical development for solid tumors, and IO-202, a first-in-class antagonist antibody targeting LILRB4 (also known as ILT3), in Phase 1b clinical development for the treatment of acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors. Additional assets in Immune-Onc’s pipeline include IO-106 (first-in-class antagonist antibody targeting LAIR1), IO-312 (a novel bispecific antibody targeting LILRB4 and CD3), and undisclosed immunology and oncology programs. For more information, please visit www.immune-onc.com.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Immune-Onc Therapeutics has 5 employees across 5 departments.
Departments
Number of employees
Immune-Onc Therapeutics Tech Stack
Discover the technologies and tools that power Immune-Onc Therapeutics's digital infrastructure, from frameworks to analytics platforms.
CDN
Font scripts
JavaScript libraries
JavaScript libraries
Development
Ecommerce
Security
JavaScript libraries
Hosting
JavaScript frameworks
Security
Miscellaneous
Canada
Germany
Australia
United KingdomFrequently asked questions
4.8
40,000 users
